Study Groups

The hepatobiliary workstream, chaired by Maria Hawkins.

Members:

Maria Hawkins, Professor in Radiation Oncology, UCL (subgroup chair)

Bristi Basu, Medical Oncologist, Academic Consultant in Experimental Cancer Therapeutics, University of Cambridge

David Bates, Professor in Oncology and Vascular Biology, University of Nottingham Centre for Cancer Sciences

Rebecca Brais, Consultant Histopathologist, Addenbrooke’s Hospital NHS Foundation Trust

John Bridgewater, Professor in Medical Oncology, UCL Cancer Institute

Saoirse Dolly, Clinical Fellow, Royal Marsden NHS Foundation Trust

Yo Green, Consumer Rep, National Cancer Research Group

Zaed Hamady, Cancer Surgeon, University Hospital Southampton NHS Foundation Trust

Timothy Kendall, Pathologist, University of Edinburgh

Shahid Khan, Consultant Gastroenterologist, Imperial College London

Yuk Ting Ma, Clinical Lecturer, King’s College London (KCL)

Hassan Malik, Consultant Hepatobiliary Surgeon and Clinical Lead of Digestive Surgery, University Hospital Aintree

Mairead Mcnamara, Honorary Consultant, Christie NHS Foundation Trust

Tim Meyer, Professor of Experimental Cancer Medicine, University College London (UCL)

Helen Morement, NCRI Consumer Forum member

Pam O’Donoghue, Lead GI Cancer Clinical Nurse Specialist, Harley Street Clinic

Kofi Oppong, Honorary Clinical Senior Lecturer, Newcastle University

Samir Pathak, Academic Clinical Lecturer/ Specialist registrar in HPB surgery, University Hospitals Bristol NHS Foundation Trust

John Primrose, Professor of Surgery, University of Southampton

Leonard Quinn, Hepatobiliary Research Fellow, Aintree University Hospital

Ganesh Radhakrishna, Consultant Clinical Oncologist, The Christie NHS Foundation Trust

Ian Rowe, Honorary Consultant Hepatologist, University of Leeds

Rohini Sharma, Consultant Medical Oncologist, Imperial College London

Juan Valle, Christie NHS Foundation Trust

Harpeet Wasan, Oncologist, Imperial College Healthcare NHS Trust – St Mary’s Hospital

Stephen Wigmore, Hepatobiliary-Pancreatic Surgical Services, University of Edinburgh

The neuroendocrine workstream, chaired by Dr Alan Anthoney, develops research into cancer of neuroendocrine cells, cells that release hormones into the bloodstream.

Members:

Alan Anthoney, Leeds Teaching Hospitals NHS Trust – Leeds General Infirmary (subgroup chair)

Cathy Bouvier, NET Patient Foundation

Martyn Caplin, University College London (UCL)

Daniel Cuthbertson, University of Liverpool

Lindsey Devlin, NET Patient Foundation

Andrea Frilling, Imperial College London

Ashley Grossman, Queen Mary University of London

Prakash Manoharan, Christie NHS Foundation Trust

Was Mansoor, Consultant in Medical Oncology, Christie NHS Foundation Trust

Mairead Mcnamara, Honorary Consultant, Christie NHS Foundation Trust

Alia Munir, Sheffield Teaching Hospitals NHS Foundation Trust

Neil Pearce, University Hospital Southampton NHS Foundation Trust

John Ramage, Hampshire Hospitals NHS Foundation Trust

Debashis Sarker, King’s College London (KCL)

Maia Sissons

Denis Talbot, Professor of Cancer Medicine, King’s College London (KCL)

Christina Thirlwell, King’s College London (KCL)

Jon Wadsley, Consultant Clinical Oncologist, Sheffield Teaching Hospitals NHS Foundation Trust

The oesophagogastric workstream, chaired by Dr Christopher Peters, develops research into cancer of the oesophagus and the stomach.

Members:

Christopher Peters, Clinical Senior Lecturer & Consultant Upper GI Surgeon, Imperial College London (subgroup chair)

Christopher Jones, Wellcome Trust Clinical Research Fellow; Honorary Specialty Registrar in Clinical Oncology, University of Leeds (subgroup assistant)

Anne Thomas, Medical Oncologist, University Hospitals of Leicester NHS Trust

Elizabeth Smyth, Clinical Research Fellow/ Consultant, Addenbrookes NHS Foundation Trust

Gareth Griffiths, Professor of Clinical Trials, Director of Southampton Clinical Trials Unit, University of Southampton

Heike Grabsch, Clinical Lecturer in Pathology, University of Leeds

Jeff Evans, Director of the Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre

John Bradwell, NCRI Consumer, NCRI Consumer Forum

Naureen Starling, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust

Richard Turkington, Clinical Senior Lecturer, Queen’s University Belfast

Russell Petty, Clinical Professor of Molecular and Clinical Medicine, University of Dundee

Ruth Langley, Oncology and Clinical Trials, University College London (UCL)

Somnath Mukherjee, Consultant Clinical Oncologist, Cancer Research UK (CRUK) Oxford – Medical Research Council (MRC), Oxford Institute for Radiation Oncology

Thomas Crosby, Clinical Director and Consultant Clinical Oncologist, Velindre Cancer Centre

Tim Underwood, Professor of GI Surgery and Clinical Scientist, University of Southampton

William Allum, Royal Marsden NHS Foundation Trust

The NCRI Pancreatic Study Group of the NCRI Upper Gastrointestinal Group launched their strategic priorities in April 2023. They comprise a multi-disciplinary community of researchers and consumers focused on developing research to improve outcomes for cancer patients and identify areas of unmet need.
Please see the NCRI Pancreatic sub-group strategic priorities 2023-2026 for further information.

Working Group 1: Identification and testing of novel therapeutics

Working closely with the PrecisionPanc team, we will establish a new Novel Therapeutics working group to promote, design and implement signal-seeking trials testing novel therapeutics, which are essential to secure success of larger scale phase III trials aimed at establishing new standards of care.

Working Group 2: Exploration of novel perioperative therapies

Building on our early pancreatic cancer framework, the Perioperative Umbrella Working Group will develop a multi-arm platform study to test different neoadjuvant and adjuvant regimens and generate signals which might justify larger scale randomised trials. The group will also seek to write a position statement on what are the key outcome measures associated with neoadjuvant therapy.

Working Group 3: Evaluate precision radiotherapy

The Radiotherapy working group will initially focus on the role of SABR in locally advanced disease and oligometastases, as part of a framework study. The aim is to understand where Stereotactic ablative radiotherapy (SABR) sits by looking at outcomes including quality of life, cost effectiveness as well as predictive biomarkers/personalisation to differentiate patients with oligorecurrence and oligoprogression versus distant metastatic disease.

Working Group 4: Improve psychosocial and supportive care for pancreatic cancer patients

We propose to bring together a multidisciplinary working group with interest and expertise to scope what is needed to improve psychosocial and supportive care needs for pancreatic cancer patients and their families, potentially generating disease-specific tools for use in routine clinics.

The pancreatic workstream is chaired by Dr Pippa Corrie.

Members:

Pippa Corrie, Consultant medical oncologist, Addenbrooke’s Hospital NHS Foundation Trust (subgroup chair)

Thankamma Ajithkumar, Consultant Clinical Oncologist, Cambridge University Hospitals NHS Foundation Trust

Bristi Basu, Medical Oncologist, Academic Consultant in Experimental Cancer Therapeutics, University of Cambridge

Andrew Biankin, Director, University of Glasgow

John Bridgewater, Professor in medical oncology, UCL Cancer Institute

David Chang, Clinical Senior Lecturer in Surgery, Wolfson Wohl Cancer Research Centre, University of Glasgow

Jeff Evans, Director of the Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre

Fieke Froeling, Consultant Medical Oncologist, University of Glasgow

Lesley Goodburn, Consumer Rep, National Cancer Research Institute (NCRI)

Richard Jackson, Senior Statistician, University of Liverpool

Nigel Jamieson, Senior Clinical Lecturer ,University of Glasgow

Hemant Kocher, Senior Lecturer & Consultant Surgeon, Barts and The London School of Medicine and Dentistry

Chris Macdonald, Head of Research, Pancreatic Cancer UK

Somnath Mukherjee, Consultant Clinical Oncologist, Cancer Research UK (CRUK) Oxford – Medical Research Council (MRC), Oxford Institute for Radiation Oncology

Eric O’Neill, CRUK/MRC Oxford Institute- Cell & Molecular Oncology (Onset & Therapy), University of Oxford

Daniel Palmer, University of Liverpool

Stephen Pereira, University College London (UCL)

David Propper, Consultant, Barts Health NHS Trust

Ganesh Radhakrishna, Consultant Clinical Oncologist -Gastrointestinal, Pancreatic, Oesophageal and hepaticopancreaticobiliary (HPB) cancers, Royal College of Radiologists

Keith Roberts, Queen Elizabeth Hospital Birmingham

Shivan Sivakumar, Academic Clinical Lecturer/ Honorary Speciality Registrar in Medical Oncology, University of Oxford

Karen Stead, Consumer Rep, National Cancer Research Institute (NCRI)

Juan Valle, Christie NHS Foundation Trust

Newton Wong, Consultant, University of Bristol